Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’

Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 2011-10, Vol.105 (9), p.1467-1467
Hauptverfasser: Gualberto, A, Hixon, M L, Pollak, M
Format: Artikel
Sprache:eng
Schlagworte:
631/45/612/1221
692/699/67/1059/2325
692/699/67/1612/1350
Biomedical and Life Sciences
Biomedicine
Cancer Research
Drug Resistance
Epidemiology
Letter to the Editor
Molecular Medicine
Oncology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1467
container_issue 9
container_start_page 1467
container_title British journal of cancer
container_volume 105
creator Gualberto, A
Hixon, M L
Pollak, M
description
doi_str_mv 10.1038/bjc.2011.413
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3241567</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2496959041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-ffde33439de68ff03f94d724751379f33342b74484fbd30ebdfdd27fe3771bfb3</originalsourceid><addsrcrecordid>eNptkdtKAzEQhoMoWKt3PkDw2q3JZtvseiFI8QRFxcN12GxmasoearJb6V0fQ1-vT2KkogheDTP_N_8M_IQccjbgTKQnelYMYsb5IOFii_T4UMQRT2O5TXqMMRmxLGa7ZM_7WWgzlsoeWT3AvFye0vXq_d5B1DrI2wrqlpawgNLTBmlhXdGVeWvrKUUHQG-uLiNOrQmYxSW9fRxPxnQegDDw9O2loQacXQAtSlvbIi-phhrQtmG9qSjaqW27qqtyvV597JMdzEsPB9-1T54vL57G19Hk7upmfD6JCpGJNkI0IEQiMgOjFJEJzBIj40QOuZAZiqDFWiZJmqA2goE2aEwsEYSUXKMWfXK28Z13ugJThF9dXqq5s1XulqrJrfqr1PZFTZuFEnHChyMZDI6-DVzz2oFv1azpXB1-VhljKRtxMQzQ8QYqXOO9A_w5wJn6ykiFjNRXRipkFPBog_uA1VNwv57_8p-kk5gQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>900806135</pqid></control><display><type>article</type><title>Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’</title><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Gualberto, A ; Hixon, M L ; Pollak, M</creator><creatorcontrib>Gualberto, A ; Hixon, M L ; Pollak, M</creatorcontrib><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2011.413</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/45/612/1221 ; 692/699/67/1059/2325 ; 692/699/67/1612/1350 ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Drug Resistance ; Epidemiology ; Letter to the Editor ; Molecular Medicine ; Oncology</subject><ispartof>British journal of cancer, 2011-10, Vol.105 (9), p.1467-1467</ispartof><rights>The Author(s) 2011</rights><rights>Copyright Nature Publishing Group Oct 25, 2011</rights><rights>Copyright © 2011 Cancer Research UK 2011 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-ffde33439de68ff03f94d724751379f33342b74484fbd30ebdfdd27fe3771bfb3</citedby><cites>FETCH-LOGICAL-c393t-ffde33439de68ff03f94d724751379f33342b74484fbd30ebdfdd27fe3771bfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241567/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241567/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids></links><search><creatorcontrib>Gualberto, A</creatorcontrib><creatorcontrib>Hixon, M L</creatorcontrib><creatorcontrib>Pollak, M</creatorcontrib><title>Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><subject>631/45/612/1221</subject><subject>692/699/67/1059/2325</subject><subject>692/699/67/1612/1350</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Letter to the Editor</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNptkdtKAzEQhoMoWKt3PkDw2q3JZtvseiFI8QRFxcN12GxmasoearJb6V0fQ1-vT2KkogheDTP_N_8M_IQccjbgTKQnelYMYsb5IOFii_T4UMQRT2O5TXqMMRmxLGa7ZM_7WWgzlsoeWT3AvFye0vXq_d5B1DrI2wrqlpawgNLTBmlhXdGVeWvrKUUHQG-uLiNOrQmYxSW9fRxPxnQegDDw9O2loQacXQAtSlvbIi-phhrQtmG9qSjaqW27qqtyvV597JMdzEsPB9-1T54vL57G19Hk7upmfD6JCpGJNkI0IEQiMgOjFJEJzBIj40QOuZAZiqDFWiZJmqA2goE2aEwsEYSUXKMWfXK28Z13ugJThF9dXqq5s1XulqrJrfqr1PZFTZuFEnHChyMZDI6-DVzz2oFv1azpXB1-VhljKRtxMQzQ8QYqXOO9A_w5wJn6ykiFjNRXRipkFPBog_uA1VNwv57_8p-kk5gQ</recordid><startdate>20111025</startdate><enddate>20111025</enddate><creator>Gualberto, A</creator><creator>Hixon, M L</creator><creator>Pollak, M</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20111025</creationdate><title>Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’</title><author>Gualberto, A ; Hixon, M L ; Pollak, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-ffde33439de68ff03f94d724751379f33342b74484fbd30ebdfdd27fe3771bfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/45/612/1221</topic><topic>692/699/67/1059/2325</topic><topic>692/699/67/1612/1350</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Letter to the Editor</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gualberto, A</creatorcontrib><creatorcontrib>Hixon, M L</creatorcontrib><creatorcontrib>Pollak, M</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gualberto, A</au><au>Hixon, M L</au><au>Pollak, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><date>2011-10-25</date><risdate>2011</risdate><volume>105</volume><issue>9</issue><spage>1467</spage><epage>1467</epage><pages>1467-1467</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><cop>London</cop><pub>Nature Publishing Group UK</pub><doi>10.1038/bjc.2011.413</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2011-10, Vol.105 (9), p.1467-1467
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3241567
source Springer Nature - Complete Springer Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects 631/45/612/1221
692/699/67/1059/2325
692/699/67/1612/1350
Biomedical and Life Sciences
Biomedicine
Cancer Research
Drug Resistance
Epidemiology
Letter to the Editor
Molecular Medicine
Oncology
title Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T05%3A49%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reply:%20%E2%80%98Pre-treatment%20levels%20of%20circulating%20free%20IGF-1%20identify%20NSCLC%20patients%20who%20derive%20clinical%20benefit%20from%20figitumumab%E2%80%99&rft.jtitle=British%20journal%20of%20cancer&rft.au=Gualberto,%20A&rft.date=2011-10-25&rft.volume=105&rft.issue=9&rft.spage=1467&rft.epage=1467&rft.pages=1467-1467&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2011.413&rft_dat=%3Cproquest_pubme%3E2496959041%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=900806135&rft_id=info:pmid/&rfr_iscdi=true